Literature DB >> 10601127

Interaction between nitric oxide and endogenous vasoconstrictors in control of renal blood flow.

H Berthold1, A Just, H R Kirchheim, H Ehmke.   

Abstract

The level of renal blood flow (RBF) is controlled by opposing vasoconstrictor and vasodilator influences. In a recent investigation in normotensive dogs, we found that combined blockade of endothelin type A (ET(A)) receptors and angiotensin II formation induces marked increases in RBF that were much larger than the effects of blocking either system alone. The aim of the present study was to determine the contribution of nitric oxide (NO) to this vasodilator response. Experiments were made in 6 conscious, chronically instrumented dogs subjected to 5 different experimental treatments on separate days. Blockade of ET(A) receptors alone by the selective antagonist LU 135252 had only minor effects on RBF compared with time-control experiments. Additional blockade of angiotensin II formation by angiotensin-converting enzyme inhibition with trandolaprilat caused a substantial increase of RBF by approximately 50%. This vasodilation was entirely suppressed when NO formation was prevented by inhibition of NO synthase with N(G)-nitro-L-arginine methyl ester HCl. However, when during NO synthase inhibition renal vascular NO concentrations were clamped at control levels by infusing the NO donor S-nitroso-N-acetyl-D, L-penicillamine, the vasodilator response to combined blockade of ET(A) receptors and angiotensin II formation was completely restored (DeltaRBF approximately 60%). These results indicate that the vasodilation after combined ET(A) receptor blockade and angiotensin-converting enzyme inhibition is not mediated by an increase in NO release but results from the unmasking of the tonic influence that is normally exerted by constitutively released NO. Accordingly, the tonic activity of endothelial NO synthase appears to be of major importance in the physiological regulation of renal vascular resistance by determining the vasomotor responses to endothelin and angiotensin II.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10601127     DOI: 10.1161/01.hyp.34.6.1254

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  5 in total

1.  Impact of endothelin A receptor antagonist selectivity in chronic nitric oxide synthase inhibition-induced fetal growth restriction in the rat.

Authors:  Mark G Neerhof; Sylvia Synowiec; Saira Khan; Larry G Thaete
Journal:  Hypertens Pregnancy       Date:  2010       Impact factor: 2.108

2.  Angiotensin II acutely decreases myocardial stiffness: a novel AT1, PKC and Na+/H+ exchanger-mediated effect.

Authors:  Adelino F Leite-Moreira; Paulo Castro-Chaves; Pedro Pimentel-Nunes; Alexandre Lima-Carneiro; Miguel S Guerra; João Bruno Soares; João Ferreira-Martins
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

3.  Renal Collectrin Protects against Salt-Sensitive Hypertension and Is Downregulated by Angiotensin II.

Authors:  Pei-Lun Chu; Joseph C Gigliotti; Sylvia Cechova; Gabor Bodonyi-Kovacs; Fang Chan; Donna Lee Ralph; Nancy Howell; Kambiz Kalantari; Alexander L Klibanov; Robert M Carey; Alicia A McDonough; Thu H Le
Journal:  J Am Soc Nephrol       Date:  2017-01-06       Impact factor: 10.121

4.  Angiotensin II stimulates melanogenesis via the protein kinase C pathway.

Authors:  Li-Hong Liu; Xin Fan; Zhi-Kuan Xia; Xu-Xi An; Rong-Ya Yang
Journal:  Exp Ther Med       Date:  2015-08-14       Impact factor: 2.447

5.  Modulation of the myogenic mechanism: concordant effects of NO synthesis inhibition and O2- dismutation on renal autoregulation in the time and frequency domains.

Authors:  Nicholas G Moss; Tayler K Gentle; William J Arendshorst
Journal:  Am J Physiol Renal Physiol       Date:  2016-01-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.